References |
1 |
Alprazolam was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
2 |
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
|
3 |
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
|
4 |
Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite
|
5 |
Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
|
6 |
Drug Interactions Flockhart Table
|
7 |
Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes
|
8 |
Changes in Alprazolam Metabolism by CYP3A43 Mutants
|
9 |
In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans
|